Literature DB >> 11988433

The Anthrax Vaccine Program: an analysis of the CDC's recommendations for vaccine use.

Meryl Nass1.   

Abstract

The anthrax vaccine was never proved to be safe and effective. It is one cause of Gulf War illnesses, and recent vaccinees report symptoms resembling Gulf War illnesses. The vaccine's production has been substandard. Without adequate evaluation, the Food and Drug Administration recently approved (retrospectively) significant changes made to the vaccine's composition since 1990. The vaccine's mandatory use for inhalation anthrax is "off-label." A skewed review of the vaccine literature by the Centers for Disease Control and Prevention (CDC) led to remunerative collaborative research with the army, involving civilian volunteers. Despite acknowledging possible fetal harm, the CDC offered the vaccine to children and pregnant women. New trends could weaken prelicensure efficacy and safety review of medical products intended for biodefense and avoid manufacturer liability for their use.

Entities:  

Keywords:  Health Care and Public Health; War and Human Rights Abuses

Mesh:

Substances:

Year:  2002        PMID: 11988433      PMCID: PMC1447151          DOI: 10.2105/ajph.92.5.715

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  18 in total

1.  Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross sectional study.

Authors:  M Hotopf; A David; L Hull; K Ismail; C Unwin; S Wessely
Journal:  BMJ       Date:  2000-05-20

Review 2.  Anthrax vaccine. Model of a response to the biologic warfare threat.

Authors:  M Nass
Journal:  Infect Dis Clin North Am       Date:  1999-03       Impact factor: 5.982

3.  Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service.

Authors:  L Steele
Journal:  Am J Epidemiol       Date:  2000-11-15       Impact factor: 4.897

4.  Reanalysis of Gulf war vaccination data does not contradict findings.

Authors:  M Hotopf
Journal:  BMJ       Date:  2000-09-23

5.  An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features.

Authors:  S A PLOTKIN; P S BRACHMAN; M UTELL; F H BUMFORD; M M ATCHISON
Journal:  Am J Med       Date:  1960-12       Impact factor: 4.965

6.  Biological products; bacterial vaccines and toxoids; implementation of efficacy review. Final rule and final order.

Authors: 
Journal:  Fed Regist       Date:  2004-01-05

7.  Chronic multisymptom illness affecting Air Force veterans of the Gulf War.

Authors:  K Fukuda; R Nisenbaum; G Stewart; W W Thompson; L Robin; R M Washko; D L Noah; D H Barrett; B Randall; B L Herwaldt; A C Mawle; W C Reeves
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

8.  Veterinary services in biological disasters.

Authors:  D L Huxsoll; W C Patrick; C D Parrott
Journal:  J Am Vet Med Assoc       Date:  1987-03-15       Impact factor: 1.936

9.  Self-reported illness and health status among Gulf War veterans. A population-based study. The Iowa Persian Gulf Study Group.

Authors: 
Journal:  JAMA       Date:  1997-01-15       Impact factor: 56.272

10.  Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.

Authors:  K C Zoon
Journal:  Emerg Infect Dis       Date:  1999 Jul-Aug       Impact factor: 6.883

View more
  8 in total

1.  From woolsorters to mail sorters: anthrax past, present, and future.

Authors:  Victor Sidel; Hillel W Cohen; Robert M Gould
Journal:  Am J Public Health       Date:  2002-05       Impact factor: 9.308

2.  Scientific evidence supports anthrax vaccination.

Authors:  George W Weightman
Journal:  Am J Public Health       Date:  2002-11       Impact factor: 9.308

3.  Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice.

Authors:  Michael S Petrik; Margaret C Wong; Rena C Tabata; Robert F Garry; Christopher A Shaw
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

4.  Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.

Authors:  Karina Ramirez; Yanina Ditamo; James E Galen; Les W J Baillie; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

5.  Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.

Authors:  James E Galen; Magaly Chinchilla; Marcela F Pasetti; Jin Yuan Wang; Licheng Zhao; Ivonne Arciniega-Martinez; David J Silverman; Myron M Levine
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

Review 6.  Anthrax vaccine and public health policy.

Authors:  Martin Meyer Weiss; Peter D Weiss; Joseph B Weiss
Journal:  Am J Public Health       Date:  2007-09-27       Impact factor: 9.308

Review 7.  Bioterrorism and the nervous system.

Authors:  M H Han; J R Zunt
Journal:  Curr Neurol Neurosci Rep       Date:  2003-11       Impact factor: 6.030

8.  A historical analysis of vaccine mandates in the United States military and its application to the COVID-19 vaccine mandate.

Authors:  Capt Brian P Elliott; Col Steven Chambers
Journal:  Vaccine       Date:  2022-08-15       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.